Please provide your email address to receive an email when new articles are posted on . A fast-acting nasal spray was safe and effective for patients self-treating for repeated episodes of paroxysmal ...

Self-administered intranasal etripamil was nearly twice as likely as placebo to terminate a paroxysmal supraventricular tachycardia (PSVT) episode within 30 minutes and reduced emergency department ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular ...

Etripamil nasal spray (Milestone Pharmaceuticals) continues to show promise as a way for patients to treat their own paroxysmal supraventricular tachycardia (PSVT) without the need for an emergency ...

In a new study, etripamil, a rapid- and short-acting investigational medication formulated to be delivered via nasal spray, restored a normal heart rhythm in less than 30 minutes in most users with ...

A nasal spray medication, pending FDA approval, shows promise for self-treating rapid heartbeats (PSVT). Etripamil effectively restored normal heart rates within 30 minutes, potentially reducing ER ...

CHICAGO -- The investigational L-type calcium channel blocker etripamil, formulated as a self-administered nasal spray, shortened spontaneous paroxysmal supraventricular tachycardia episodes among ...

A fast-acting medication delivered as a nasal spray may someday allow patients with intermittent rapid heartbeats to treat it themselves as soon as they develop symptoms, according to new research ...